期刊
ONCOLOGY REPORTS
卷 45, 期 3, 页码 997-1010出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/or.2021.7947
关键词
glioma-associated oncogene homolog 2; hedgehog signal; gallbladder cancer; cell cycle; epithelial-mesenchymal transition; tumor microenvironment; tumor infiltrating lymphocyte; programmed cell death ligand 1; hypoxia
类别
资金
- Japan Society for the Promotion of Science KAKENHI [18K08620]
- Grants-in-Aid for Scientific Research [18K08620] Funding Source: KAKEN
This study revealed that GLI2 is involved in various aspects of GBC, such as cell proliferation, invasion, and sensitivity to treatment, suggesting it could be a novel therapeutic target for GBC. The results provide significant insights for the development of new treatment options for refractory GBC.
We previously reported that Hedgehog (Hh) signal was enhanced in gallbladder cancer (GBC) and was involved in the induction of malignant phenotype of GBC. In recent years, therapeutics that target Hh signaling have focused on molecules downstream of smoothened (SMO). The three transcription factors in the Hh signal pathway, glioma-associated oncogene homolog 1 (GLI1), GLI2, and GLI3, function downstream of SMO, but their biological role in GBC remains unclear. In the present study, the biological significance of GLI1, GLI2, and GLI3 were analyzed with the aim of developing novel treatments for GBC. It was revealed that GLI2, but not GLI1 or GLI3, was involved in the cell cycle-mediated proliferative capacity in GBC and that GLI2, but not GLI1 or GLI3, was involved in the enhanced invasive capacity through epithelial-mesenchymal transition. Further analyses revealed that GLI2 may function in mediating gemcitabine sensitivity and that GLI2 was involved in the promotion of fibrosis in a mouse xenograft model. Immunohistochemical staining of 66 surgically resected GBC tissues revealed that GLI2-high expression patients had fewer numbers of CD3(+) and CD8(+) tumor-infiltrating lymphocytes (TILs) and increased programmed cell death ligand 1 (PD-L1) expression in cancer cells. These results suggest that GLI2, but not GLI1 or GLI3, is involved in proliferation, invasion, fibrosis, PD-L1 expression, and TILs in GBC and could be a novel therapeutic target. The results of this study provide a significant contribution to the development of a new treatment for refractory GBC, which has few therapeutic options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据